Danaher forward PE DHR
Share price divided by analysts' consensus earnings for the next twelve months, since 1996.
- Today, Oct 23, 2026
- 25.4×
- 10-year median
- 25.6×
- Against its 10-year history
- 45th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 17.9× to 39.6×
- Peer median
- 27.8×
Danaher's forward PE is 25.4× as of Oct 23, 2026.
That is below its ten-year median of 25.6×, close to the middle of its last ten years.
Over that time it ranged from 17.9× in Aug 2017 to 39.6× in Aug 2024.
The median for 10 diagnostics and research stocks of a similar size is 27.8×.
Forward PE over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 25.4× | 19.0× | 30.3× |
| 2025 | 29.3× | 24.1× | 34.4× |
| 2024 | 32.3× | 32.0× | 39.6× |
| 2023 | 34.2× | 24.8× | 34.2× |
| 2022 | 26.6× | 22.5× | 29.1× |
| 2021 | 29.7× | 22.4× | 30.3× |
| 2020 | 25.1× | 20.5× | 30.6× |
| 2019 | 28.7× | 19.4× | 28.8× |
| 2018 | 19.7× | 18.8× | 22.4× |
| 2017 | 20.0× | 17.9× | 20.4× |
| 2016 | 18.7× | 11.8× | 20.2× |
| 2015 | 13.1× | 12.0× | 14.3× |
| 2014 | 14.5× | 12.5× | 14.9× |
| 2013 | 14.7× | 11.7× | 14.7× |
| 2012 | 11.3× | 10.3× | 11.9× |
| 2011 | 10.3× | 9.4× | 13.3× |
| 2010 | 12.4× | 10.0× | 12.9× |
| 2009 | 12.6× | 9.7× | 12.8× |
| 2008 | 10.8× | 9.9× | 15.4× |
| 2007 | 14.5× | 12.5× | 14.5× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Danaher's size, closest first, today.
| Company | Forward PE |
|---|---|
| DHRDanaher | 25.4× |
| TMOThermo Fisher Scientific | 25.0× |
| AAgilent Technologies | 26.4× |
| IQVIQVIA | 20.5× |
| WATWaters | 29.2× |
| IDXXIDEXX Laboratories | 35.9× |
| ILMNIllumina | 47.2× |
| MTDMettler-Toledo International | 33.9× |
| DGXQuest Diagnostics | n/m |
| LHLabcorp | 17.4× |
| MEDPMedpace | n/m |
| Peer median | 27.8× |
Where Danaher ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on Danaher
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.